| 摘要 |
A compound of formula (I), where: R(1) is halogen; hydroxyl; (C1-C4)alkoxy; (C1-C8)alkoxy, wherein 1 to 6 carbon atoms are replaced by the heteroatoms O, S, or NH, (C1-C4)-alkoxy, substituted by a saturated cyclic ether; O-(C1-C4)-alkenyl; O-(C1-C4)-alkylaryl; or phenoxy, unsubstituted or substituted by a substituent selected from halogen, (C1-C3)-alkyl, (C1-C3)-alkoxy, and trifluoromethyl; R(2) is CHO; COOH; or CO-O-(C1-C4)-alkyl; R(3) is (C1-C4)-alkyl; or aryl; R(4) is hydrogen; halogen; or (C1-C4)-alkyl; X is oxygen or sulfur; Y is oxygen or -NH-; R(5) is hydrogen; (C1-C6)-alkyl; or (C1-C4)-alkylaryl; where R(5) can only be hydrogen if Y is -NH-; and R(6) is (C1-C5)-alkyl with the proviso that compounds of the formula (I) in which R(1) is halogen and R(2) is COOH or CO-O-(C1-C4)-alkyl are excluded. Also described is a pharmaceutical preparation comprising the compound of formula (I). The compounds of formula (I) as defined above (but where the proviso restricting the values of R(1) and R(2) described above does not apply) are useful for the treatment and/or prophylaxis of illnesses which are primarily or secondarily caused or at least partly caused by reduced production and/or release of the vasorelaxant, antithrombotic and cardioprotective messengers cyclic 3',5'-guanosine monophosphate (cGMP) and nitrogen monoxide (NO).
|
